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Abstract. This paper primarily summarizes the work
done under the guidance of Dr. Bruce Chabner in
1975 and 1976. During these years I studied the role
of drug concentration, duration of exposure, and
endogenous metabolites in determining methotrex-
ate (MTX) cytotoxicity to the bone marrow stem cell
(CFU-C). We found that the rate of loss of CFU-C
during continuous intravenous infusion of methotrex-
ate was related to the duration of exposure until the
nadir in cell count was reached at 24 hours. Depletion
of nucleated cells was mitigated, probably as a result
of recruitment of previously uncommitted precursor
cells to CFU-C, even while the MTX infusion was
continued up to 48 hours. In vitro it was shown that
methotrexate and leucovorin were transported com-
petitively in the CFU-C, which was in clear contrast
with rescue agents such as thymidine and nucleoside
analogs. After my training my work has continued
in close contact with Dr. Chabner, while the scope of
both our interests broadened to include the MDR
field. My own interest focused on functional studies in
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In December 1974 I arrived at the medical
branch of the NCI. Unfortunately, my host had
taken a job elsewhere, so I felt I was left in the
lurch in a huge institute in a foreign country. It
was clear to me that I had to put together my
own program. At that time I had never heard of
Bruce Chabner. I sat down for a full week in the
library studying bone marrow physiology and
stem cell culture. At that same time I was
intrigued by the introduction of high-dose
methotrexate (MTX) into the clinic as a new
treatment for osteosarcoma. My second topic to
study was the preclinical pharmacology of this
antimetabolite which seemed to be making furor.
So another week was spent in the library to get
acquainted with the pharmacology of MTX. The
days thereafter were spent putting the two sub-
jects together and preparing a workplan, which I
presented to Joan Bull on the 3rd floor.
As I needed mice and a spectrophotometer,
I intruded on the 6th floor and introduced myself
to Dan Zaharko. I was offered space in the ani-
mal room and a bench next to a spectropho-
tometer. On a day in February, 1975, while
measuring mouse plasma samples of MTX, I
bumped into Bruce Chabner, who kept observing
me working in the Pharmacology Branch. He
asked for my research plan and was truly inter-
ested in my ideas. Soon thereafter we discussed
my plan in detail. It seemed that the potential
clinical impact of my work was constantly in his
focus. In short, my project would study the effect
of MTX concentration and its duration of expo-
sure on the bone marrow stem cell, both in vitro
and in vivo. This was the beginning of a very
intense collaboration with Bruce.
The difficult early days proved to be the start
of a most exciting year, in fact the most exciting
one in my research career. This was a year with-
out any administrative headaches, without respon-
sibilities for running any department. In order to
study the effect of constant exposure of MTX on
bone marrow CFU-C, I used a glass tube device
developed by Dan Zaharko. I am still very grate-
ful to him. Indeed, he also had a very critical look
at the data I generated. The infusion device per-
mitted s.c. infusion of MTX into mice at a con-
stant rate. Physical characteristics of devices
ranging in size were studied. Plateau plasma con-
centrations of MTX (1 × 10–8 M to 1 × 10–5 M)
achieved from infusion rates varying over three
orders of magnitude (<1 to >100 µg/hour) were
studied and evaluated in terms of toxicity and
pharmacokinetic behavior of this drug. 
The effects of exposure of bone marrow to
specific MTX concentrations were studied by
constant infusion of the drug into mice. The resid-
ual marrow nucleated cell count was determined
in mice at specific intervals. In vitro culture of
CFU-C was also performed in these mice.
Duration of exposure varied from 12 h to 72 h.
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Plateau plasma MTX concentrations were studied
in the range from 10–8 to 10–5 M. Unexpectedly,
the total number of nucleated cells per femur fell
to a plateau of 30% of control for all drug concen-
trations studied. The nadir was reached earliest
with the highest drug concentrations. The per-
centage of CFU-C per fixed number of nucleated
cells plated increased at 48-hour infusions, com-
pared to the percentage at 24 h. This increase was
seen at all plasma concentrations studied. The
total number of CFU-C at plasma MTX concen-
trations above 10–6 M decreased in the first 24 h,
but then the number significantly increased
between 24 h and 48 h. In contrast, no change
was observed in CFU-C per femur between 24 h
and 48 h during constant infusion at plasma con-
centrations below 10–6 M. Constant exposure to
10–5 M MTX produced a rapid decrease in total
nucleated cells to 35% at 12 h, which remained at
approximately this level throughout 48 h of drug
infusion. A decrease in the number of both
CFU-C and CFU-S per femur was observed,
which paralleled the drop in nucleated cells dur-
ing the first 24 h. However, in contrast to the
increase in CFU-C during the next 24 h, an addi-
tional drop in the number of CFU-S was observed
at this high concentration. These data indicated
a self-limited cell kill of nucleated bone marrow
cells, and suggested recruitment of CFU-C from
the CFU-S pool between 24 h and 48 h of infusion
despite continued MTX infusion. 
Thereafter, the cytotoxic effect of MTX for
mouse bone marrow cells was studied by in vitro
culture of granulocyte precursor cells (CFU-C).
The formation of colonies was inhibited to 50%
of control by 10–8 M MTX. Further increases in
MTX concentration rapidly abolished colony for-
mation by CFU-C. The potential of leucovorin
and nucleosides to rescue the CFU-C from MTX
toxicity was studied. Toxicity of 10–7 M MTX
was completely reversed by equimolar concen-
trations of leucovorin, but with higher MTX con-
centrations, relatively more leucovorin was
required. While MTX was rescued by leucov-
orin, rescue of the toxic effect of 10–4 M MTX
by 10–3 M leucovorin was not observed. In contrast
to the rescue by leucovorin, toxicity of all MTX
concentrations up to 10–4 M was completely pre-
vented by 10–5 M thymidine with 10–5 M adeno-
sine, inosine, or hypoxanthine. Single nucleosides
of thymidine with guanosine were ineffective, as
were lower concentrations (≤10–6 M) of the effec-
tive combinations. Thus, while leucovorin reversed
the MTX toxicity to CFU-C competitively, rescue
by nucleosides was noncompetitive. 
Since my return to the Netherlands in 1976
my scientific work continued to focus on cellu-
lar pharmacology. In the beginning, I performed
several in vitro experiments on L1210 cells.
Grossly, the findings were pretty much in agree-
ment with the in vitro observations for the
CFU-C’s. In those days Al Leyva, who was rec-
ommended by Dr. Chabner, joined my group in
Utrecht. In the eighties, after moving with my
group to Amsterdam, the MTX work made way
for 5 fluorouracil and PALA. The type of studies
did not change, however. Studies now focused
on the target enzymes. Cellular resistance in the
MDR field gradually came into focus, a field into
which both Bruce and I moved. Because of the
potential presence of a number of cellular pro-
teins keeping the drugs from reaching their tar-
gets, my group switched to functional assays.
We first applied acute myeloid leukemia as a
model, but more recently we are attempting to
dissociate solid tumors to perform similar func-
tional studies. However, the tumor stroma is mak-
ing such an approach extremely difficult. In the
clinic we both embarked on MDR reverting trials.
Our trials with reverting agents in solid tumors
have been quite disappointing. At this year’s
AACR, Bruce will be organizing a symposium on
controversies in this field, which without any
doubt will be of great interest. Part of the dis-
cussion will be the lack of predictiveness of pre-
clinical models of drug resistance for the clinic. 
It may ultimately appear that we have been
focusing too much on Pgp as a resistance marker,
while reality is closer to Pgp being a marker for
aggressiveness. Pgp might appear to be an ATP-
dependent pump for endogenous components. If
true, one would expect its affinity for such com-
pounds to be higher, and with a higher concen-
tration of the biological products at the pump than
of any reverter administered. This would leave a
very narrow window for reverters and for clinical
trials to be successful. The situation may prove
slightly different for acute leukemia and myeloma
where the extracellular concentration of the
reverter may be sufficient to compete with
endogenous produces.
Bruce Chabner and Dan Longo joined me
as editors of the successful Cancer Chemotherapy
Annual. Moreover, I have greatly appreciated
Bruce’s co-chairmanship of the NCI/EORTC
New Drug Symposia during the past 10 years.
In conclusion, more than 20 years have passed
since Bruce Chabner triggered my interest in the
field of pharmacology of antineoplastic agents.
Both our research interests were initially domi-
nated by the antimetabolites. Thereafter, there
was a broadening of the scope with the intro-
duction of the MDR research. As with his other
disciples, I have maintained close contact with
him despite our physical distance, exchanging
data on a routine basis.
